| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:1957.)
© 2004 American Heart Association, Inc.
Original Contributions |
From the Departments of Internal Medicine (S.D., C.D.S., F.M.F., S.R.L.), Physiology and Biophysics (C.D.S.), and Pharmacology (F.M.F.), University of Iowa Carver College of Medicine, Iowa City, Iowa; Baylor Institute of Metabolic Disease (E.A., T.B.), Dallas, Texas; the Institute of Experimental and Clinical Pharmacology and Toxicology (R.H.B.), University Hospital Hamburg-Eppendorf, Hamburg, Germany; and the Veterans Affairs Medical Center (S.R.L.), Iowa City, Iowa.
Correspondence to Dr Steven R. Lentz, Department of Internal Medicine, C303 GH, The University of Iowa, Iowa City, IA 52242. E-mail steven-lentz{at}uiowa.edu
| Abstract |
|---|
|
|
|---|
Methods Mice heterozygous for a targeted disruption of the cystathionine ß-synthase gene (Cbs+/) and their wild type littermates (Cbs+/+) were fed either a control diet or a high-methionine diet for 10 to 12 months.
Results Plasma total homocysteine was elevated with the high-methionine diet compared with the control diet for both Cbs+/+ (7.9±1.0 versus 5.0±0.5 µmol/L; P<0.05) and Cbs+/ (20.5±3.1 versus 8.2±0.9 µmol/L; P<0.001) mice. Dilatation of cerebral arterioles (
30 µm baseline diameter) was measured in vivo in response to the endothelium-dependent dilator acetylcholine or the endothelium-independent dilator nitroprusside. Vasodilatation to acetylcholine was impaired with the high-methionine diet compared with the control diet for both Cbs+/+ and Cbs+/ mice (P<0.01). Dilatation of arterioles to acetylcholine was restored toward normal by the superoxide scavenger tiron (P<0.05). Vasodilatation to nitroprusside was not influenced by Cbs genotype or diet. Dihydroethidium (DHE) staining for vascular superoxide was elevated in Cbs+/ mice fed the high-methionine diet and was inhibited by apocynin or N
-nitro-L-arginine methyl ester, implicating NAD(P)H oxidase and nitric oxide synthase as potential sources of superoxide.
Conclusions Superoxide is a key mediator of endothelial dysfunction in the cerebral circulation during diet-induced hyperhomocysteinemia.
Key Words: cerebral endothelium homocysteine stroke superoxides
| Introduction |
|---|
|
|
|---|
10% higher risk of cardiovascular disease and
20% greater risk of stroke after adjustment for other known risk factors.2 Hyperhomocysteinemia has also been implicated as a risk factor for cerebral venous thrombosis3 and Alzheimer disease.4 Studies in animals and humans have demonstrated that hyperhomocysteinemia is associated with impaired endothelium-dependent dilatation of the aorta and other peripheral vessels.5 Hyperhomocysteinemic mice with heterozygosity for a targeted disruption of the cystathionine ß-synthase (Cbs) gene have enhanced sensitivity to endothelial dysfunction in the aorta and mesenteric arterioles.6,7 Endothelial dysfunction in peripheral arteries during hyperhomocysteinemia is associated with decreased bioavailability of the endothelium-derived vasodilator, nitric oxide (NO).8 Proposed mechanisms include oxidative inactivation of NO and decreased production of NO due to inhibition of endothelial nitric oxide synthase (NOS) by asymmetric dimethylarginine (ADMA).8
Much less is known about the effects of hyperhomocysteinemia in cerebral blood vessels. Using mice heterozygous for disruption of the Cbs gene, it was demonstrated recently that mild hyperhomocysteinemia promotes cerebral vascular hypertrophy and altered cerebral vascular mechanics.9 Zhang et al found that superfusion of the rat parietal cortex with a combination of Cu2+ and a very high concentration (1 mmol/L) of homocysteine decreased cerebral blood flow and attenuated responses to endothelium-dependent vasodilators.10 In humans, acute methionine loading has been reported to impair cerebral vascular reactivity in older but not younger subjects.11 It is not known, however, if chronic hyperhomocysteinemia produces cerebral vascular dysfunction in vivo, or whether effects of hyperhomocysteinemia on cerebral blood vessels are mediated by oxidative stress.
In this study, we used the Cbs-deficient mouse model to test the hypothesis that chronic hyperhomocysteinemia produces endothelial dysfunction in cerebral arterioles in vivo. Our results indicate that cerebral vascular dysfunction occurs at levels of plasma tHcy that are associated with clinical hyperhomocysteinemia in humans, and that this effect is mediated in part by superoxide.
| Materials and Methods |
|---|
|
|
|---|
Responses in Cerebral Arterioles
Dilatation of cerebral arterioles was measured as described.13 Briefly, mice were anesthetized with sodium pentobarbital and ventilated mechanically. A cranial window was made over the left parietal cortex, and a segment of a randomly selected pial arteriole (
30 µm in diameter) was exposed. The diameter of the cerebral arteriole was measured using a video microscope coupled to an image-shearing device under control conditions and during superfusion with acetylcholine (1 and 10 µmol/L) and nitroprusside (0.1 and 1 µmol/L). In some experiments the window was superfused with 10 mmol/L tiron (4,5-dihydroxy-1,3, benzene-disulfonic acid) for 30 minutes before superfusion with acetylcholine.
Detection of Superoxide
Dihydroethidium (DHE), an oxidative fluorescent dye, was used to detect superoxide in sections of common carotid artery or cerebral arterioles by laser scanning confocal microscopy as described.14 Some sections were preincubated for 30 minutes with either PBS, 250 U/mL polyethylene glycol-superoxide dismutase (PEG-SOD) (Sigma-Aldrich), 300 µmol/L apocynin (4-hydroxy-3-methoxy acetophenone) (Fluka), 100 µmol/L N
-nitro-L-arginine methyl ester (L-NAME) (Sigma-Aldrich), or 20 µmol/L uric acid (Calbiochem) before incubation with DHE. Fluorescent images were analyzed with Scion Image software (more details available at http://www.scioncorp.com). Data are reported as the percentage of surface area of carotid sections within the upper 20% of fluorescence intensity.
Plasma tHcy, Methionine, and ADMA
Blood was collected in anesthetized mice by cardiac puncture into EDTA (final concentration 5 mmol/L) for measurement of plasma tHcy and ADMA. Plasma tHcy, defined as the total concentration of homocysteine after quantitative reductive cleavage of all disulfide bonds, was measured by high-performance liquid chromatography (HPLC) and SBDF (ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate) fluorescence detection.15 Plasma methionine was measured by HPLC with coulometric electrochemical detection as described.7 Plasma ADMA was determined by HPLC using precolumn derivatization with 0-phthalaldehyde.16
Statistical Analysis
Two-way analysis of variance (ANOVA) followed by Tukey post-hoc test was used to analyze the effects of Cbs genotype and diet on plasma tHcy, ADMA, and responses to vasodilators in cerebral arterioles. The MannWhitney rank sum test was used for comparisons of DHE fluorescence data. Correlation coefficients were calculated using the Pearson product moment correlation. A value of P<0.05 was used to define statistical significance. Values are reported as mean±SE.
| Results |
|---|
|
|
|---|
|
Responses in Cerebral Arterioles
Mean arterial pressure of anesthetized mice was similar in Cbs+/+ and Cbs+/ mice (73±6 versus 70±4 mm Hg for the control diet and 73±5 versus 70±3 mm Hg for the high methionine diet, respectively). Acetylcholine produced concentration-dependent dilatation of cerebral arterioles of both Cbs+/+ and Cbs+/ mice (Figure 1A and 1B). In mice fed the control diet, responses to acetylcholine tended to be diminished in Cbs+/ mice compared with Cbs+/+ mice (13±1.2 versus 16±2.5% for 1.0 µmol/L acetylcholine and 22±1.8 versus 27±3.5% for 10 µmol/L acetylcholine), but these differences did not reach statistical significance (P>0.10). In mice fed the high methionine diet, responses to acetylcholine were significantly impaired in both Cbs+/+ and Cbs+/ mice compared with mice of the same genotypes fed the control diet (P<0.05). This effect of the high methionine diet was lost after cerebral arterioles were pretreated with the superoxide scavenger tiron (10 mmol/L) (Figure 1A and 1B). Responses to 1.0 µmol/L acetylcholine improved significantly after pretreatment with tiron in both Cbs+/+ and Cbs+/ mice fed the high methionine diet (P<0.05). Responses to 10 µmol/L acetylcholine also improved after pretreatment with tiron in mice fed the high methionine diet; this effect was significant for Cbs+/+ mice (P<0.05), but not for Cbs+/ mice (P>0.10). Concentration-dependent responses to nitroprusside were not affected by Cbs genotype or diet (P>0.10) (Figure 2).
|
|
Vascular Superoxide
Superoxide production was measured in sections of carotid artery using DHE. In the presence of superoxide, DHE is oxidized to a fluorescent adduct that intercalates into DNA, producing a nuclear staining pattern.17 As observed previously,17,18 DHE fluorescence was observed throughout the vascular wall. DHE fluorescence was detected at similar levels in Cbs+/+ and Cbs+/ mice fed the control diet and Cbs+/+ mice fed high methionine diet (Figure 3), but fluorescence was elevated 2.7±0.5-fold in Cbs+/ mice fed the high methionine diet (P<0.01 versus Cbs+/+ mice fed the control diet). The fluorescence signal in Cbs+/ mice fed the high methionine diet was inhibited by 250 U/mL polyethylene glycol-superoxide dismutase (PEG-SOD) (Figure 4B), which demonstrates that superoxide was a major reactive oxygen species detected by DHE in these vessels.
|
|
To examine potential sources of vascular superoxide, sections of carotid artery from Cbs+/ mice fed the high methionine diet were preincubated with an inhibitor of NAD(P)H oxidase, apocycin (300 µmol/L), or an inhibitor of NOS, L-NAME (100 µmol/L), before DHE staining. Each of these inhibitors decreased DHE fluorescence by
40% (Figure 4C and 4D), which implicates both NAD(P)H oxidase and NOS as sources of vascular superoxide in hyperhomocysteinemic mice. DHE fluorescence also was inhibited by preincubation with uric acid (20 µmol/L), an inhibitor of peroxynitrite-mediated oxidation19 (Figure 4E).
Superoxide also was detected by DHE staining in cerebral arterioles (Figure 5). Although we were unable to obtain quantitative data because of the small size of the vessels, DHE fluorescence clearly was higher in Cbs+/+ or Cbs+/ mice fed the high methionine diet (Figure 5C and 5D) compared with the control diet (Figure 5A and 5B). DHE fluorescence in cerebral arterioles was markedly inhibited by PEG-SOD (Figure 5E).
|
| Discussion |
|---|
|
|
|---|
Despite strong epidemiological evidence linking hyperhomocysteinemia and stroke,1,2 very few studies have examined functional effects of hyperhomocysteinemia in cerebral blood vessels. Using a rat model, Zhang et al10 demonstrated that superfusion of the parietal cortex with exogenous homocysteine and Cu2+ decreased cerebral blood flow and attenuated responses to endothelium-dependent vasodilators.10 Interestingly, the vascular effects of homocysteine/Cu2+ were prevented by co-administration of superoxide dismutase, which suggested a potential role for superoxide.10 A major limitation of this study was that both exogenous Cu2+ and a very high concentration of exogenous homocysteine (1 mmol/L) were needed to observe these effects. Our current findings confirm and extend these observations in a murine model that produces levels of plasma tHcy similar to those in human subjects at increased risk for stroke because of moderate hyperhomocysteinemia.1 Our results also are in concordance with a recent study in which acute methionine loading was found to impair cerebral vascular reactivity in elderly human subjects.11
There is growing evidence that hyperhomocysteinemia promotes the oxidative inactivation of endothelium-derived NO in peripheral arteries.8 Our findings with the superoxide scavenger, tiron, suggest that oxidative inactivation of NO also occurs in the cerebral microcirculation. DHE fluorescence in Cbs+/ mice fed the high methionine diet was inhibited by apocycin (Figure 4), which suggests that one source of vascular superoxide in hyperhomocysteinemic mice is an NAD(P)H oxidase. Vascular NAD(P)H oxidases are expressed in endothelium and vascular smooth muscle and have been implicated as sources of superoxide in atherosclerosis, hypertension, and diabetes.20 Our results are consistent with the recent findings of Ungvari et al,21 who detected increased NADPH-dependent production of superoxide and increased expression of the NAD(P)H oxidase subunit nox1 in coronary arteries isolated from hyperhomocysteinemic rats.
We also found that DHE fluorescence was inhibited by L-NAME, which suggests that NOS may be another source of vascular superoxide in hyperhomocysteinemia. Biochemical "uncoupling" of NOS, which can be caused by oxidation of its cofactor tetrahydrobiopterin, results in the preferential production of superoxide rather than nitric oxide. Uncoupling of NOS during hyperhomocysteinemia may be mediated by peroxynitrite, a powerful oxidant that is formed through the reaction of superoxide with NO.22 We found that DHE fluorescence in Cbs+/ mice fed a high methionine diet was decreased by uric acid (Figure 4), an inhibitor of peroxynitrite-mediated oxidation.19 We also considered the possibility that vascular superoxide is related to ADMA, an endogenous NOS inhibitor that may promote uncoupling of NOS.23 ADMA is derived from protein methylation reactions that produce homocysteine as a byproduct, and plasma ADMA is elevated during hyperhomocysteinemia in monkeys and humans.23 Only a modest effect of Cbs genotype on plasma ADMA was seen in the current study (Table 1), however, which suggests that plasma ADMA is unlikely to be a major mediator of endothelial dysfunction during hyperhomocysteinemia in mice.
We observed diet-induced impairment of endothelium-dependent dilatation of cerebral arterioles not only in Cbs+/ mice with moderate hyperhomocysteinemia (plasma tHcy
20 µmol/L), but also in Cbs+/+ mice with very mild hyperhomocysteinemia (plasma tHcy
8 µmol/L tHcy) (Figure 1). This observation contrasts with previous findings using aortic rings from Cbs+/+ and Cbs+/ mice in which only Cbs+/ mice with plasma tHcy >20 µmol/L exhibited impaired responses to acetylcholine.7 These results suggest that cerebral arterioles may be more sensitive than the aorta to the vascular effects of mild hyperhomocysteinemia. In support of this interpretation, hypertrophy of cerebral arterioles has been observed in Cbs+/+ and Cbs+/ mice with mild hyperhomocysteinemia (plasma tHcy >8 µmol/L).9 It is noteworthy, however, that responses of cerebral arterioles to acetylcholine were preserved in Cbs+/ mice fed the control diet (Figure 1), despite the fact that these mice also had mild elevation of plasma tHcy (
8 µmol/L). This finding raises the possibility that a methionine metabolite other than homocysteine may contribute to cerebral vascular dysfunction during dietary hyperhomocysteinemia. Another possibility is that mean daily levels of tHcy may have been higher in Cbs+/+ mice fed the high methionine diet than in Cbs+/ mice fed the control diet because of augmented diurnal variation.14
Several factors can be considered that may account for the greater influence of diet-induced hyperhomocysteinemia on cerebral arterioles as opposed to the aorta. First, the small size of cerebral arterioles (
30 µm diameter) may enhance their susceptibility to oxidative damage. In this regard, it is interesting that small mesenteric arterioles in mice also appear to be highly sensitive to modest elevations of plasma tHcy.6 Second, the importance of endothelium-derived NO, as opposed to other mediators of endothelium-dependent dilatation, such as products of cyclooxygenase activity or an endothelium-derived hyperpolarizing factor (EDHF), may vary in different blood vessels. We consider it unlikely that the greater sensitivity to hyperhomocysteinemia of cerebral arterioles compared with aorta is related to endothelium-derived mediators other than NO because responses to acetylcholine in both aorta and cerebral arterioles in mice are almost completely dependent on NO.13 It also seems unlikely that increased production of EDHF compensates for the loss of endothelium-derived NO because hyperhomocysteinemia appears to inhibit vascular responses mediated by EDHF in renal vessels.24 However, we cannot exclude the possibility that responses to acetylcholine in hyperhomocysteinemic mice are mediated in part by EDHF. Third, differences in experimental methods (dilatation of cerebral arterioles in anesthetized mice in vivo versus relaxation of aortic rings in vitro) may partly explain the greater apparent sensitivity of cerebral vessels to mild hyperhomocysteinemia. Although the contributing factors will require further study, our current findings clearly demonstrate that cerebral arterioles are sensitive to endothelial dysfunction caused by diet-induced hyperhomocysteinemia.
In summary, we have demonstrated that murine cerebral arterioles are susceptible to endothelial dysfunction during diet-induced hyperhomocysteinemia. Our data suggest that the mechanism of dysfunction is related to increased vascular superoxide, which may be produced by vascular NAD(P)H oxidase and NOS or both. The propensity of cerebral vessels to develop oxidative stress may account for the high prevalence of stroke, vascular dementia, and other cerebrovascular diseases in human subjects with hyperhomocysteinemia.
| Acknowledgments |
|---|
Received February 12, 2003; revision received March 31, 2004; accepted April 20, 2004.
| References |
|---|
|
|
|---|
2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA. 2002; 288: 20152022.
3. Martinelli I, Battaglioli T, Pedotti P, Cattaneo M, Mannucci PM. Hyperhomocysteinemia in cerebral vein thrombosis. Blood. 2003; 102: 13631366.
4. Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, DAgostino RB, Wilson PW, Wolf PA. Plasma homocysteine as a risk factor for dementia and Alzheimers disease. N Eng J Med. 2002; 346: 476483.
5. Lentz SR. Homocysteine and cardiovascular physiology. In: Carmel R, Jacobsen DW, eds. Homocysteine in Health and Disease. Cambridge, UK: Cambridge University Press; 2001: 441450.
6. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Tolliet M, Heyrick S, Stark R, Klings ES, Moldovan NI, Yaghoubi M, Goldschmidt-Clermont PJ, Farber HW, Cohen R, Loscalzo J. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest. 2000; 106: 483491.[Medline] [Order article via Infotrieve]
7. Dayal S, Bottiglieri T, Arning E, Maeda N, Malinow MR, Sigmund CD, Heistad DD, Faraci FM, Lentz SR. Endothelial dysfunction and elevation of S-adenosylhomocysteine in cystathionine ß-synthase-deficient mice. Circ Res. 2001; 88: 12031209.
8. Faraci FM. Hyperhomocysteinemia: a million ways to lose control. Arterioscler Thromb Vasc Biol. 2003; 23: 371373.
9. Baumbach GL, Sigmund CD, Bottiglieri T, Lentz SR. Structure of cerebral arterioles in cystathionine beta-synthase-deficient mice. Circ Res. 2002; 91: 931937.
10. Zhang F, Slungaard A, Vercellotti GM, Iadecola C. Superoxide-dependent cerebrovascular effects of homocysteine. Am J Physiol. 1998; 274: R1704R1711.[Medline] [Order article via Infotrieve]
11. Chao CL, Lee YT. Impairment of cerebrovascular reactivity by methionine-induced hyperhomocysteinemia and amelioration by quinapril treatment. Stroke. 2000; 31: 29072911.
12. Watanabe M, Osada J, Aratani Y, Kluckman K, Reddick R, Malinow MR, Maeda N. Mice deficient in cystathionine ß-synthase: animal models for mild and severe homocyst(e)inemia. Proc Natl Acad Sci U S A. 1995; 92: 15851589.
13. Sobey CG, Faraci FM. Effects of a novel inhibitor of guanylyl cyclase on dilator responses of mouse cerebral arterioles. Stroke. 1997; 28: 837842.
14. Dayal S, Brown KL, Weydert CJ, Oberley LW, Arning E, Bottiglieri T, Faraci FM, Lentz SR. Deficiency of glutathione peroxidase-1 sensitizes hyperhomocysteinemic mice to endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2002; 22: 19962002.
15. Ubbink JB, Hayward Vermaak WJ, Bissbort S. Rapid high-performance liquid chromatographic assay for total homocysteine levels in human serum. J Chromatogr. 1991; 565: 441446.[Medline] [Order article via Infotrieve]
16. Böger RH, Lentz SR, Bode-Böger SM, Knapp HR, Haynes WG. Elevation of asymmetric dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inemia in humans. Clin Sci. 2001; 100: 161167.[Medline] [Order article via Infotrieve]
17. Münzel T, Afanasev IB, Kleschyov AL, Harrison DG. Detection of superoxide in vascular tissue. Arterioscler Thromb Vasc Biol. 2002; 22: 17611768.
18. Miller FJ Jr, Gutterman DD, Rios CD, Heistad DD, Davidson BL. Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circ Res. 1998; 82: 12981305.
19. Squadrito GL, Cueto R, Splenser AE, Valavanidis A, Zhang H, Uppu RM, Pryor WA. Reaction of uric acid with peroxynitrite and implications for the mechanism of neuroprotection by uric acid. Arch Biochem Biophys. 2000; 376: 333337.[CrossRef][Medline] [Order article via Infotrieve]
20. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000; 86: 494501.
21. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, Koller A. Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol. 2003; 23: 418424.
22. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, Tarpey M, Fukai T, Harrison DG. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation. 2001; 103: 12821288.
23. Lentz SR, Rodionov RN, Dayal S. Hyperhomocysteinemia, endothelial dysfunction, and cardiovascular risk: the potential role of ADMA. Atheroscler Suppl. 2003; 4: 6165.[Medline] [Order article via Infotrieve]
24. De Vriese AS, Blom HJ, Heil SG, Mortier S, Kluijtmans LAJ, Van de Voorde J, Lameire N. Endothelium-derived hyperpolarizing factor-mediated renal vasodilatory response is impaired during acute and chronic hyperhomocysteinemia. Circulation. 2004; 109: 23312336.
This article has been cited by other articles:
![]() |
P. S. Ganapathy, B. Moister, P. Roon, B. A. Mysona, J. Duplantier, Y. Dun, T. K. V. E. Moister, M. J. Farley, P. D. Prasad, K. Liu, et al. Endogenous Elevation of Homocysteine Induces Retinal Neuron Death in the Cystathionine-{beta}-Synthase Mutant Mouse Invest. Ophthalmol. Vis. Sci., September 1, 2009; 50(9): 4460 - 4470. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dayal and S. R. Lentz Murine Models of Hyperhomocysteinemia and Their Vascular Phenotypes Arterioscler Thromb Vasc Biol, September 1, 2008; 28(9): 1596 - 1605. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dayal, R. N. Rodionov, E. Arning, T. Bottiglieri, M. Kimoto, D. J. Murry, J. P. Cooke, F. M. Faraci, and S. R. Lentz Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia Am J Physiol Heart Circ Physiol, August 1, 2008; 295(2): H816 - H825. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. C. Looft-Wilson, B. S. Ashley, J. E. Billig, M. R. Wolfert, L. A. Ambrecht, and S. E. Bearden Chronic diet-induced hyperhomocysteinemia impairs eNOS regulation in mouse mesenteric arteries Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2008; 295(1): R59 - R66. [Abstract] [Full Text] [PDF] |
||||
![]() |
P.-Y. Chang, S.-C. Lu, C.-M. Lee, Y.-J. Chen, T. A. Dugan, W.-H. Huang, S.-F. Chang, W. S.L. Liao, C.-H. Chen, and Y.-T. Lee Homocysteine Inhibits Arterial Endothelial Cell Growth Through Transcriptional Downregulation of Fibroblast Growth Factor-2 Involving G Protein and DNA Methylation Circ. Res., April 25, 2008; 102(8): 933 - 941. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. C. Newman, H. Bang, S. I. Hussain, and J. F. Toole Association of diabetes, homocysteine, and HDL with cognition and disability after stroke Neurology, November 27, 2007; 69(22): 2054 - 2062. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Suematsu, C. Ojaimi, S. Kinugawa, Z. Wang, X. Xu, A. Koller MD, F. A. Recchia, and T. H. Hintze Hyperhomocysteinemia Alters Cardiac Substrate Metabolism by Impairing Nitric Oxide Bioavailability Through Oxidative Stress Circulation, January 16, 2007; 115(2): 255 - 262. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Colgan and R. C. Austin Homocysteinylation of Metallothionein Impairs Intracellular Redox Homeostasis: The Enemy Within! Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 8 - 11. [Full Text] [PDF] |
||||
![]() |
G. I. Stangl, K. Weisse, C. Dinger, F. Hirche, C. Brandsch, and K. Eder Homocysteine Thiolactone-Induced Hyperhomocysteinemia Does Not Alter Concentrations of Cholesterol and SREBP-2 Target Gene mRNAs in Rats Experimental Biology and Medicine, January 1, 2007; 232(1): 81 - 87. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Wilson, R. B. McCaw, L. Leo, E. Arning, S. Lhotak, T. Bottiglieri, R. C. Austin, and S. R. Lentz Prothrombotic Effects of Hyperhomocysteinemia and Hypercholesterolemia in ApoE-Deficient Mice Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 233 - 240. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Ohashi, M. S. Runge, F. M. Faraci, and D. D. Heistad MnSOD Deficiency Increases Endothelial Dysfunction in ApoE-Deficient Mice Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2331 - 2336. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dayal, K. M. Wilson, L. Leo, E. Arning, T. Bottiglieri, and S. R. Lentz Enhanced susceptibility to arterial thrombosis in a murine model of hyperhomocysteinemia Blood, October 1, 2006; 108(7): 2237 - 2243. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kitayama, F. M. Faraci, C. A. Gunnett, and D. D. Heistad Impairment of Dilator Responses of Cerebral Arterioles During Diabetes Mellitus: Role of Inducible NO Synthase Stroke, August 1, 2006; 37(8): 2129 - 2133. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. Faraci Reactive oxygen species: influence on cerebral vascular tone J Appl Physiol, February 1, 2006; 100(2): 739 - 743. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Kamath, A. K. Chauhan, J. Kisucka, V. S. Dole, J. Loscalzo, D. E. Handy, and D. D. Wagner Elevated levels of homocysteine compromise blood-brain barrier integrity in mice Blood, January 15, 2006; 107(2): 591 - 593. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Andresen, N. I. Shafi, and R. M. Bryan Jr. Endothelial influences on cerebrovascular tone J Appl Physiol, January 1, 2006; 100(1): 318 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Kerkeni, F. Addad, M. Chauffert, A. Myara, M. Ben Farhat, A. Miled, K. Maaroufi, and F. Trivin Hyperhomocysteinemia, Endothelial Nitric Oxide Synthase Polymorphism, and Risk of Coronary Artery Disease Clin. Chem., January 1, 2006; 52(1): 53 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tan, X. Jiang, F. Yang, Z. Li, D. Liao, J. Trial, M. J. Magera, W. Durante, X. Yang, and H. Wang Hyperhomocysteinemia inhibits post-injury reendothelialization in mice Cardiovasc Res, January 1, 2006; 69(1): 253 - 262. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dayal, A. M. Devlin, R. B. McCaw, M.-L. Liu, E. Arning, T. Bottiglieri, B. Shane, F. M. Faraci, and S. R. Lentz Cerebral Vascular Dysfunction in Methionine Synthase-Deficient Mice Circulation, August 2, 2005; 112(5): 737 - 744. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Devlin, T. Bottiglieri, F. E. Domann, and S. R. Lentz Tissue-specific Changes in H19 Methylation and Expression in Mice with Hyperhomocysteinemia J. Biol. Chem., July 8, 2005; 280(27): 25506 - 25511. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dayal and S. R Lentz ADMA and hyperhomocysteinemia Vascular Medicine, July 1, 2005; 10(1_suppl): S27 - S33. [Abstract] [PDF] |
||||
![]() |
T. Kawaguchi, S. W. Brusilow, R. J. Traystman, and R. C. Koehler Glutamine-dependent inhibition of pial arteriolar dilation to acetylcholine with and without hyperammonemia in the rat Am J Physiol Regulatory Integrative Comp Physiol, June 1, 2005; 288(6): R1612 - R1619. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Dayal and S. R Lentz ADMA and hyperhomocysteinemia Vascular Medicine, May 1, 2005; 10(2_suppl): S27 - S33. [Abstract] [PDF] |
||||
![]() |
J. S. Becker, A. Adler, A. Schneeberger, H. Huang, Z. Wang, E. Walsh, A. Koller, and T. H. Hintze Hyperhomocysteinemia, a Cardiac Metabolic Disease: Role of Nitric Oxide and the p22phox Subunit of NADPH Oxidase Circulation, April 26, 2005; 111(16): 2112 - 2118. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. M. Faraci Oxidative Stress: The Curse That Underlies Cerebral Vascular Dysfunction? Stroke, February 1, 2005; 36(2): 186 - 188. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |